BioSpace News Archive

Hillrom (NYSE: HRC) announced today that its board of directors declared a fiscal 2020 first quarter dividend of $0.21 per share payable on December 31, 2019, to shareholders of record as of the close of business on December 16, 2019.

BERG, a clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the underlying biology of disease, today announced results from a study of its investigational drug BPM31510 (ubidecarenone) characterizing its immunomodulatory properties ex vivo and in tumor bearing mice

Boston Biomedical, Inc. today announced the presentation of new data from a phase 1 study evaluating DSP-7888, an investigational WT1 cancer peptide vaccine, in patients with advanced malignancies.

Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting data at the SITC Annual Meeting in National Harbor, Maryland on November 9, 2019.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will report third quarter 2019 results on Tuesday, November 12, 2019

Gossamer Bio, Inc. (Nasdaq: GOSS), today announced that two abstracts supporting GB001, the Company’s oral DP2 antagonist for the treatment of asthma and allergic disease, have been accepted for presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 2019 being held November 7- 11 in Houston, Texas.

Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced that Dr. Mark Sirgo, Chief Executive Officer, and Dr. Steve Stice, Chief Scientific Officer, will be presenting at the 31st Annual Piper Jaffray Healthcare Conference in New York City on Thursday, December 5th at 8:10 AM Eastern time.

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is comparable to those for subcutaneous immunotherapy (SCIT) for environmental allergies.

Ocugen, Inc.,, a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, reported financial highlights for the third quarter of 2019 and a business update.

BerGenBio’s proprietary Composite AXL Tumor-Immune Score predicts patients that have significantly prolonged clinical benefit